CHFR (Checkpoint with fork-head associated and ring finger) by Erson-Bensan, Ayse E et al.
Gene Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(1) 1 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
CHFR (Checkpoint with fork-head associated 
and ring finger) 
Ayse E Erson-Bensan, Hesna Begum Akman, Elizabeth M Petty 
Department of Biology, Middle East Technical University, Ankara, Turkey (AEEB, HBA); University 
of Wisconsin School of Medicine, Public Health, Madison, WI 53705-2221, USA (EMP) 
Published in Atlas Database: December 2014 
Online updated version : http://AtlasGeneticsOncology.org/Genes/CHFRID526.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62503/12-2014-CHFRID526.pdf  
DOI: 10.4267/2042/62503
This article is an update of : 
Erson AE, Petty EM. CHFR (Checkpoint with fork-head associated and ring finger). Atlas Genet Cytogenet Oncol Haematol 
2004;8(3) 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Growing evidence in mice, primary human tumors, 
and mammalian cell culture models indicate that 
CHFR may function as a potent tumor suppressor. 
CHFR functions as part of an early G2/M 
checkpoint, more specifically in antephase. 
Antephase refers to late G2 when chromosome 
condensation starts.  This early mitotic checkpoint 
causes a delay in chromosome condensation in 
response to mitotic stresses. The human CHFR gene 
was originally identified during a search for novel 
cell cycle checkpoint proteins that have fork-head 
associated domains. Initial analysis indicated that the 
CHFR-associated G2/M checkpoint was inactivated 
in a subset of cancers as demonstrated by high 
mitotic indices (a high percentage of cells that have 
condensed chromosomes) in response to exposure to 
the microtubule poison, nocodazole, due to lack of 
CHFR expression or CHFR mutations in various 
cancers.  Many other studies showed promoter 
hypermethylation leading to low/no expression of 
CHFR. 
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Identity 
HGNC (Hugo): CHFR 
Location: 12q24.33 
Other names: FLJ10796 
Local order 
Genes flanking CHFR in centromere to telomere 
direction on 12q24.33: 
Peroxisomal membrane protein 2 gene (PXMP2) --- 
Hypothetical protein gene (MGC5352) --- Golgi 
autoantigen, golgin subfamily a3 gene (GOLGA3) -
-- Checkpoint with FHA and RING finger gene 
(CHFR) --- Hypothetical gene (GeneID: 90462) --- 
Zinc finger protein 26 gene (ZNF26) 
Note 
CHFR functions as part of an early G2/M 
checkpoint, more specifically in antephase. 
Antephase refers to late G2 when chromosome 
condensation starts.  
This early mitotic checkpoint causes a delay in 
chromosome condensation in response to mitotic 
stresses. The human CHFR gene was originally 
identified during a search for novel cell cycle 
checkpoint proteins that have fork-head associated 
domains. Initial analysis indicated that the CHFR-
associated G2/M checkpoint was inactivated in a 
subset of cancers as demonstrated by high mitotic 
indices (a high percentage of cells that have 
condensed chromosomes) in response to exposure to 
the microtubule poison, nocodazole, due to lack of 
CHFR expression or CHFR mutations in a 
neuroblastoma, an osteosarcoma and 2 colon cancer 
cell lines (4 of 8 different cancer cell lines) (Scolnick 
and Halazonetis, 2000).  
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Domains of CHFR. The forkhead-associated domain of CHFR is located at the N-terminus. RING-finger domain with the 
ubiquitination activity is located through 303-346 amino acids. Poly-ADP-ribose binding zinc finger motif overlaps with the 
cystein-rich region near the C-terminus. 
 
Various further studies demonstrated loss of or low 
CHFR expression in various types of cancer cells 
including those from colon, esophageal, gastric, lung 
and breast cancers.  
Over time, CHFR has been identified as an 
inactivated tumor suppressor protein in a diverse 
group of solid tumor malignancies, mostly as 
demonstrated by promoter CpG island methylation. 
DNA/RNA 
Description 
The CHFR gene spans approximately 47 kb and has 
at least 18 exons (BC012072 vs. NT_024477) as 
predicted according to Spidey 
(http://www.ncbi.nlm.nih.gov/spidey/) 
http://www.ncbi.nlm.nih.gov/spidey/). While 
multiple splice forms have been demonstrated 
(Toyota et al, 2003), the genomic structure has not 
been experimentally confirmed. 
Transcription 
CHFR mRNA is 3189 bp (BC012072).  
Transcripts that lack exon 2, exon 5 and exon 6 have 
been detected in various tissues including bone 
marrow, small intestine, lung, heart, testis, kidney, 
stomach and lympocytes as well as some cancer cell 
lines by RT-PCR. Northern blot transcript analysis 
suggests that limited if any alternative splicing is 
present in most fetal and adult tissues where CHFR 
is expressed a prominent 3.2 kb is observed. CHFR 
mRNA is detected in heart, brain, placenta, lung, 
liver, muscle, kidney, pancreas by Northern blot 
analysis (Scolnick and Halazonetis, 2000). 
Alternative mRNA transcripts lacking specific exons 
(2, 5, and/or 6) have been described for CHFR 
(Toyota et al. 2003) The  isoform that lacks exon 2 
happens to lack the FHA domain and was also found 
to be highly expressed in cancer cells when 
compared to normal samples . 
Pseudogene 
No known pseudogene has been reported 
Protein 
Description 
CHFR encodes a 652 amino acid protein (according 
to BC012072 nucleotide sequence) with FHA 
(forkhead associated), RING (really interesting new 
gene) finger and cysteine rich domains. Cysteine rich 
region further harbors a PBZ domain. No alternative 
isoforms have been described to date. 
Domains: 
- FHA domains (16-123) are present in cell cycle 
checkpoint genes, transcription factors, protein 
kinases and have roles in protein-protein interactions 
with specificity for phosphorylated targets.  
The three dimensional structure of CHFR suggests 
that CHFR may be able to recognize as of yet 
unidentified phosphorylated targets targets (Stavridi 
et al., 2002; Tsai 2002).. 
- RING finger domains are found in ubiquitin 
ligases.  
Ubiquitin ligases attach ubiquitin to target proteins 
during a cascade of enzymatic reactions. RING 
finger domains are present in a variety of proteins 
(e.g. Anaphase promoting complex, APC, Cbl 
family proteins, MDM2) implicated in cancer. 
- Cys: Cystein-rich region (476-641) 
- PBZ: poly-ADP-ribose binding zinc finger motif 
(620-644) is at the C terminus. PBZ domain allows 
CHFR to bind to poly (ADP-ribose). This domain is 
generally required for the activity of checkpoint 
response proteins (Ahel et al., 2008) 
Expression 
CHFR is ubiquitiously expressed in normal fetal and 
adult human tissues.  
Protein levels are predicted to fluctuate during the 
cell cycle possibly through auto-ubiquitination based 
on overexpression studies in cancer cell lines 
(Chaturverdi et al., 2002; Kim et al., 2011).  
Upon mitotic stresses, CHFR protein levels are 
thought to be stabilized and reaching the highest 
levels at G2/M. 
Localisation 
Various lines of evidence suggest different cellular 
localizations for CHFR. Endogenous and low 
ectopic expression of CHFR showed cytoplasm and 
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spindle localization patterns during mitosis. Higher 
expression of ectopic CHFR correlated with a shift 
in the localization to the nucleus (Burgess et al., 
2008). Later on, nuclear presence of CHFR was 
explained via a short lysine-rich stretch (KKK) at 
amino acid residues 257-259 (Kwon et al., 2009). 
Egeberg et al., 2012 suggested a centrosome/primary 
cilium axis localization of CHFR. CHFR was also 
shown to localize to the mitotic spindle by an 
interaction with TCTP, a protein involved in 
microtubule stabilization and a-tubulin (Kim, 2011) 
Function 
Initially, CHFR was described to induce an early 
G2/M checkpoint in response to mitotic stress 
(Scolnick and Halozenetis, 2000). Cell lines 
expressing wild-type CHFR exhibit low mitotic 
index (percentage of cells with condensed 
chromosomes) and delayed entry into metaphase 
when centrosome separation is inhibited by mitotic 
stress. In contrast, cancer cell lines lacking CHFR 
function enter metaphase without delay and 
demonstrate higher mitotic indices compared to the 
CHFR expressing cell lines. (Erson and Petty, 2004). 
In vitro studies suggest that the RING finger domain 
in CHFR also facilitates ubiquitin ligase function 
and that it is essential for checkpoint function of 
CHFR (Chaturved et al., 2002).. In vitro Xenopus 
extract experiments suggested that CHFR 
specifically targets PLK1 (polo-like kinase 1) for 
degradation when extracts are supplemented with 
high ubiquitin concentrations (Kang, 2002). Thus, 
according to this in vitro model, CHFR is able to halt 
cell cycle progression early in mitosis by degrading 
PLK1, a major player for the activation of mitosis 
promoting factor. In addition, AURORA A is known 
to phosphorylate and activate PLK1 as well as 
CDC25B eventually driving CYCLIN B/CDK1 
activation. Interestingly, CHFR was also found to 
bind via its cysteine rich C-region and ubiquitinate 
AURORA A, leading to its degradation (Yu et al., 
2005). The auto-ubiquitylation ability of CHFR at 
G2 Phase was proposed to be required for the 
accumulation of Plk1 and mitotic entry in 
mammalian cells (Kim et al., 2011). Earlier, Oh et 
al., showed deubiquitination of Chfr, by 
USP7/HAUSP (deubiquitinating enzyme) also to 
regulate its own stability and activity (Oh et al,. 
2007). 
On the contrary, Summers et al. suggested PLK1 and 
AURORA A levels not to change when CHFR was 
expressed in HCT116 cells treated with Nocodazole 
(Summers et al., 2005). 
More recently, other proteins including TOPK and 
PTEN have been shown to play a role in the CHFR 
related mitotic spindle checkpoing (Shinde et al. 
2013) 
Furthermore, Bothos et al., showed that CHFR was 
able to activate the p38 stress kinase pathway, which 
reverses chromosome condensation and induces a 
mitotic arrest and suggested that the ubiquitin ligase 
function of CHFR may be different than the current 
in vitro model and that instead of Lys48 
ubiquitination, CHFR may link ubiquitin to target 
protein or proteins via Ly63 due to its interaction 
with the heteromeric ubiquitin conjugating enzyme 
complex, Ubc13-Mms2 (Bothos et al., 2003).  
In the canonical ubiquitin/proteasome pathway, 
Lys48 is a signal for degradation of target proteins 
whereas Lys63 ubiquitination functions as a non-
proteolytic tag for protein targets. Lys63 
ubiquitination is thought to be involved in DNA 
repair mechanisms. Indeed, CHFR appears to have 
important roles in DNA damage response 
(Shtivelman et al., 2003). CHFR and RNF8 (A 
ubiquin ligase) ubiquitinate histones (H2A and H2B) 
upon ioinizing radiation (Al-Hakim et al., 2010; Wu 
et al., 2011).  
These ubiquitinations seem to be important for the 
eventual activation of the key DNA damage 
checkpoint effector, ATM (Derks et al., 2006; Lavin 
and Kozlov, 2007).  
Recently, CHFR was reported to interact with 
MAD2, an important component of the spindle 
assembly checkpoint. CHFR knockdown resulted in 
mislocalization of MAD2 and disruption of the 
MAD2/CDC20 interaction.  
The cysteine-rich region of CHFR appears to be the 
essential domain for the CHFR/MAD2 interaction 
and for promoting interaction between MAD2 and 
CDC20 to inhibit the anaphase-promoting complex 
(Privette et al., 2008; Keller and Petty, 2011). 
Homology 
M.musculus 5730484M20Rik RIKEN cDNA 
5730484M20 gene, R.norvegicus LOC288734  
similar to RIKEN cDNA 5730484M20, budding 
yeast proteins, Dma1 and Dma2 are 58% identical to 
each other and are possible homologs of human 
CHFR. Dma1 and Dma2 have roles in spindle 
formation and formation of septin ring during 
cytokinesis (Fraschini et al., 2004). 
Mutations 
Germinal 
No germline mutations have been reported yet. 
Somatic 
A panel of 53 lung carcinomas has been screened 
with matching normal tissue and 3 mutations were 
found, one of which was associated with loss of 
heterozygosity. Mutations found in patient samples 
were: C587T, G695C (both between the FHA and 
RING domains) and T1697C (in the C-terminal 
cysteine rich region of CHFR). However, no 
correlation was found with a specific diagnosis or 
stage of the disease in the patients (Mariatos et al., 
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2003). No clear pathogenic mutations in the CHFR 
coding sequence have been observed in the analysis 
of tumors (Privette and Petty, 2008). 
Epigenetics 
Hypermethylation of the CHFR promoter has been 
the most commonly reported mechanism lowering 




In gastric cancer, methylation of CHFR promoter is 
highly recurrent (Hu et al., 2011; Li et al., 2014; 
Satoh et al., 2003). Decreased CHFR expression has 
been shown in 20% of gastric cell lines and 39% of 
primary gastric cancers tested (Satoh et al., 2003). In 
a study with 102 paraffin-embedded gastric cancer 
samples, 34% of samples showed methylation. No 
association was found between methylation of 
CHFR promoter with gender, age, tumor size, tumor 
differentiation, and lymph node metastasis. 
According to Cox proportional hazards model in 
docetaxel-treated gastric cancer patients, resistance 
to docetaxel was found in CHFR unmethylated 
patients. CHFR methylation may serve as a 
docetaxel-sensitive marker in human gastric cancer 
(Li et al., 2014). 
Lung cancer 
Loss of detectable CHRF levels has been linked to 
aberrant hypermethylation in lung cancer (Mizuno et 
al., 2002). Apart from hypermethylation, 
inactivation of CHFR gene by missense mutations is 
reported for lung carcinomas (Mariatos et al., 2003). 
In a study with 165 lung carcinomas, 10% were 
found to have hypermethylated CHFR promoter. In 
addition, 
Prognosis 
CHFR hypermethylation was significantly 
correlated with poor prognosis of lung carcinomas, 
suggesting a therapeutic potential for CHFR targeted 
approaches (Koga et al., 2013). 
Cytogenetics 
A lung cancer patient sample demonstrates loss of 
heterozygosity for a CA repeat located on a BAC that 
contains the CHFR gene. Several other cancers 
demonstrate allelic imbalance involving 
chromosome band 12q24 but specific analysis of 
CHFR in these samples has not been investigated. 
Breast cancer 
An initial screening resulted with 50% of 24 breast 
cancer cell lines to have CHFR expression (Erson 
and Petty, 2004). CHFR protein levels were also low 
in 36% of breast cancer patients. Lack of CHFR 
expression in primary cancers was associated with 
increased tumor size and estrogen receptor 
negativity (Privette et al., 2007). In another study, 
110 primary breast cancers were investigated for 
methylation status, only 0.9% showed 
hypermethylation of CHFR promoter (Tokunaga et 
al., 2006). Although hypermethylation of CHFR 
promoter is common in various cancers, this study 
showed it to be a rare event in primary breast 
carcinomas. Moreover, an interaction between 
CHFR and PARP-1 was shown to have an important 
role in cell cycle regulation.  CHFR, by its E3 
ubiquitin ligase function, caused degradation of 
PARP-1, which lead to cell cycle arrest in prophase. 
These findings suggested a novel potential 
therapeutic approach for combinational 
chemotherapy with PARP inhibitors for breast 
cancer cells (Kashima et al., 2012). 
Leukemia 
Methylation of CHFR promoter was detected in 39% 
of leukemia patients. CHFR hypermethylation 
incidence was shown to be unchanged between acute 
myelocytic leukemia and acute lymphocytic 
leukemia (Gong et al., 2005). 
Esophageal cancer 
When expression level of CHFR was investigated, 4 
out of 15 esophageal cancer cell lines (26.7%) and 7 
out of 43 (16.3%) primary esophageal cancers 
showed loss of CHFR expression due to 
hypermethylation of promoter (Shibata et al., 2002). 
In another study, CHFR transcript was found to be 
downregulated in 79% of esophageal 
adenocarcinomas (44 of 56 samples) compared to 41 
normal samples. Immunohistochemical analysis also 
correlated with expression analysis, 75% (56 of 75) 
of samples showed either weak or no 
immunostaining. Hypermethylation of promoter 
correlated with low CHFR expression in esophageal 
cancer patients; 31% of samples (18 of 58) displayed 
significant hypermethylation (Soutto et al., 2010). 
Another recent study used 40 esophageal squamous 
cell carcinoma patient samples for RT-qPCR 
analysis of CHFR expression. Aberrant 
hypermethylation of the CHFR promoter was 
observed in 13 of 29 primary esophageal cancers. 
The CHFR expression levels of the methylated 
samples was significantly lower than that of the 
unmethylated samples (Suzuki et al., 2014) 
Hepatocellular carcinoma 
Aberrant methylation was detected in 22 of 65 (35%) 
primary hepatocellular carcinomas (HCC), 
compared to noncancerous liver cells (Sakai et al., 
2005). Also, methylation of CHFR was found to be 
significantly correlated with advanced disease stage 
(p=0.037) and an infiltrated growth pattern 
(p=0.047). In another study with 70 HCC samples, 
methylation frequency of CHFR was 43% (30 out of 
70) (Li et al., 2012). 5-aza-2'-deoxycytidine (5-aza-
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dC) treatment of HCC cell lines restored expression 
of CHFR. 
Prostate cancer 
In a genome profiling study, blood and bone-marrow 
samples of prostate cancer patients were investigated 
using methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) 
(Schwarzenbach et al., 2011). MS-MLPA detected 
genetic and epigenetic aberrations of 37 tumor 
suppressor genes including CHFR. 
Head and neck cancer 
19% of 126 head and neck cancer patients showed 
methylation of a group of tumor suppressors. CHFR 
was one of the most frequently methylated genes in 
tumor tissue compared to normal (Yalniz et al., 
2011). 
Cervical cancer 
Out of 14 cervical adenocarcinoma specimens tested 
by methylation-specific PCR, 2 of them (12.3%) 
showed aberrant methylation of CHFR (Banno et al., 
2007). When six cell lines derived from human 
cervical carcinoma were analyzed, hypermethylaton 
of CHFR was observed in HeLa and SKG-IIIb cells. 
In another study, sequential methylation of eight 
genes including CHFR was linked to HPV-induced 
cervical carcinogenesis (Henken et al., 2007). 
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